heart-disease
(4)
Us2.ai
Us2.ai is a Singapore-based medtech company that builds FDA-cleared, CE-marked AI software to automate echocardiography (cardiac ultrasound) analysis and reporting. Its vendor-neutral platform - branded the AI Echo Copilot - turns raw DICOM echo studies into fully editable, structured clinical reports in seconds, detecting conditions such as heart failure, aortic stenosis, pulmonary hypertension and cardiac amyloidosis. Founded in 2017 as eko.ai and rebranded to Us2.ai in 2021, the company aims to widen access to expert-level cardiac diagnostics across hospitals, echo labs and clinical-trial core labs worldwide.
Cleerly
Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.
Performance Kitchen | Food Is Medicine®
Performance Kitchen | Food Is Medicine® is an Austin, Texas company that produces chef-crafted, dietitian-approved Medically Tailored Meals designed to help manage chronic conditions such as diabetes, heart disease, and renal disease. Founded in 2011 as a healthy consumer food brand sold in more than 10,000 retail stores, the company pivoted to lead the Food Is Medicine movement, delivering ready-to-eat meals that are increasingly paid for by health insurers and delivered directly to members' homes. Led by Chairman and CEO Mark Walker, a CPA and founder of athlete-backed Dugout Ventures, Performance Kitchen operates nationwide production and distribution reaching roughly 98% of the U.S.
Bitterroot Bio
Bitterroot Bio is a Palo Alto, California clinical-stage biotechnology company pioneering the field of cardio-immunology - the science of how the immune system drives heart disease. Founded by veterans of Forty Seven (the CD47 company Gilead bought for ~$5 billion), Bitterroot is turning the immune-checkpoint playbook from cancer toward atherosclerosis. Its lead candidate, BRB-002, is an immunomodulating protein that blocks the CD47 'don't eat me' signal on arterial plaque, prompting macrophages to clear inflammation and stabilize plaque - a mechanism that works differently from cholesterol-lowering drugs. The company launched out of stealth in June 2023 with a $145 million Series A, which it called the largest-ever round for a preclinical cardiovascular biotech.